Monte Rosa Therapeutics, Inc. GLUE
At closeNov 6, 2026, 5:23 PM EST
After hours · Nov 6, 5:23 PM ET
- YTD
- -32.59%
- 1 year
- -18.75%
- Market cap
- 901.76M
- Revenue (ttm)
- 28.73M
- EPS (ttm)
- -1.39
- Shares out
- 85.31M
- Forward P/E
- -6.37
- YTD return
- -32.59%
- 1-year return
- -18.75%
- Volume
- 1.01M
- Avg volume
- 1.29M
- Open
- 10.30
- Previous close
- 10.25
- Day's range
- 9.89 – 10.67
- 52-week range
- 9.74 – 25.31
- Beta
- 1.50
- Price target
- 28.50 (+169.6%)
- Earnings date
- Nov 5, 2026
5D -0.31 (-2.85%)
Key statistics
- Enterprise value
- 418.46M
- PEG ratio
- 0.00
- Price / sales
- 35.43
- Price / book
- 2.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -61.30%
- Free cash flow
- -74.45M
- Total cash
- 621.10M
- Total debt
- 37.99M
- Return on equity
- -42.66%
- Short % of float
- 22.94%
- 50-day average
- 15.55
- 200-day average
- 18.27
Analyst view
- Target (low)
- 25.00
- Target (mean)
- 28.50
- Target (high)
- 37.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.22694.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.22694 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.38048 | -0.43 | -0.05 | -13.02% |
| May 7, 2026 | Mar 31, 2026 | -0.28 | -0.45 | -0.17 | -60.71% |
| Mar 17, 2026 | Dec 31, 2025 | -0.35153 | -0.54 | -0.19 | -53.61% |
| Nov 6, 2025 | Sep 30, 2025 | -0.36634 | -0.33 | +0.04 | +9.92% |
| Aug 7, 2025 | Jun 30, 2025 | -0.37683 | -0.15 | +0.23 | +60.19% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 25, 2026 | Guggenheim | reit | Buy | Buy |
| Aug 7, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 7, 2026 | Guggenheim | main | Buy | Buy |
| Aug 7, 2026 | Wells Fargo | main | Overweight | Overweight |
| Aug 3, 2026 | Wedbush | main | Outperform | Outperform |
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- monterosatx.com
News
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $25 
Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates 
Monte Rosa Therapeutics Q3 EPS $0.03 Beats $(0.29) Estimate, Sales $54.366M Beat $29.750M Estimate 
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates 
Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? 
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences 
Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis 
Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis 
HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target
Your note
Sign in to keep a note on GLUE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOWEN MATTHEW | Officer | Stock Award(Grant) | Apr 5, 2026 | 25,904 |
| CHAMPOUX JENNIFER | Chief Operating Officer | Sale | Jul 14, 2026 | 62,371 |
| DUNN EDMUND | Officer | Sale | Mar 3, 2026 | 22,554 |
| JANKU FILIP | Officer | Sale | Jun 29, 2026 | 60,612 |
| LEO CHANDRA P. MD | Director | Purchase | Mar 23, 2025 | 10,000 |
| MANNING ANTHONY M | Director | Sale | Jun 28, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Associates Inc | 10.39% | 8,861,171 | 105.71M | Jun 29, 2026 |
| NEA Management Company, LLC | 9.02% | 7,692,298 | 91.77M | Jun 29, 2026 |
| Blackrock Inc. | 8.02% | 6,843,087 | 81.64M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 5.42% | 4,622,151 | 55.14M | Jun 29, 2026 |
| Vestal Point Capital, LP | 5.39% | 4,600,000 | 54.88M | Jun 29, 2026 |
| BVF Inc. | 5.23% | 4,460,886 | 53.22M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 2,550,827 | 30.43M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 2.62% | 2,232,091 | 26.63M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.62% | 2,231,487 | 26.62M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.23% | 1,899,251 | 22.66M | Aug 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 2.14% | 1,823,210 | 21.75M | Jun 29, 2026 |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 1.61% | 1,375,639 | 16.41M | Jun 29, 2026 |